莫西沙星序贯治疗社区获得性肺炎临床研究

目的研究莫西沙星治疗社区获得性肺炎的临床疗效、安全性。方法216例轻中度社区获得性肺炎患者随机分为3组。A组（观察组）予莫西沙星序贯治疗，B组（对照组）予左氧氟沙星序贯治疗，C组（对照组）予头孢曲松钠／头孢泊肟酯联合阿奇霉素常规序贯治疗。结果①A组、B组和C组痊愈率分别为70．3％（52／74）、67．1％（47／70）和47．2％（34／72），临床有效率分别为86．5％（64／74）、82．9％（58／70）和72．2％（52／72），细菌清除率分别84．8％（28／33）、82．1％（23／28）和58．1％（18／31），3个指标中，A、B两组间差异均无统计学意义，A、C两组间差异均有统计学意义；②A组、B组和C组静脉注射时间分别为（2．27±1．14）d、（2．33±1．15）d和（3．03±1．08）d，A、B两组间差异无统计学意义，A、C两组间差异有统计学意义；③A组、B组和C组不良反应发生率分别为5．4％（4／74）、5．7％（4／70）和13．9％（10／72），A、B两组间差异无统计学意义，A、C两组间差异有统计学意义。结论莫西沙星序贯治疗社区获得性肺炎效果更为确切、安全。

The clinical research of sequential moxifloxacin therapy in patients with community acquired pneumonia

Objective To evaluate the efficacy and safety of sequential moxifloxacin therapy in the treatment of patients with community acquired pneumonia.Methods One hundred and sixteen patients with community acquired pneumonia were randomly divided into three groups.In group A (moxifloxacin sequential group),moxifloxacin was administered by intravenous infusion 400 mg/250 ml once daily until to appear "clinical standard" of intravenous infusion turned into oral administration,followed by oral administration at the same dose.The total treatment duration was also 7～12 days.In group B (control group),levofloxacin was administered by intravenous infusion 0.2 g/250 ml twice daily until to appear "clinical standard" of intravenous infusion turned into oral administration,followed by oral administration 0.1 g twice daily.The total treatment duration was also 7～12 days.In group C(control group),ceftriaxone sodium was administered by intravenous infusion 2.0 g/250 ml once daily until to appear "clinical standard" of intravenous infusion turned into oral administration,followed by oral administration Cefpodoxime 0.1 g twice daily with Azithromycin 0.5 g once daily.The total treatment duration was also 7～12 days.Results The overall cure rates and efficacy rates were 70.3%and 86.5% in group A,67.1% and 82.9% in group B,47.2% and 72.2% in group C,respectively.The bacterial clearance rates were 84.8% in group A,82.1% in group B,58.1% in group C,respectively.There was no significant difference(P＞0.05) between group A and group B,and there was significant difference(P＜0.05)between group A and group C in the above results.The time of appearing "clinical standard" of intravenous infusion turned into oral administration were(2.27 ± 1.14)d in group A,(2.33 ± 1.15)d in group B,(3.03 ±1.08)d in group C,respectively.There was no significant difference(P＞0.05)between group A and group B,and there was significant difference(P＜0.05)between group A and group C in the above results.The incidence of adverse drug reactions of three groups were 5.4% 、5.7% and 13.9%,respectively.There was no significant difference (P＞0.05) between group A and group B,and there was significant difference (P＜0.05) between group A and group C in the above results.Conclusion Sequential moxifloxacin therapy in patients with community acquired pneumonia was more effective and safe.